vs

Side-by-side financial comparison of C4 Therapeutics, Inc. (CCCC) and TAYLOR DEVICES, INC. (TAYD). Click either name above to swap in a different company.

TAYLOR DEVICES, INC. is the larger business by last-quarter revenue ($11.6M vs $11.0M, roughly 1.1× C4 Therapeutics, Inc.). TAYLOR DEVICES, INC. runs the higher net margin — 17.3% vs -186.0%, a 203.3% gap on every dollar of revenue. On growth, C4 Therapeutics, Inc. posted the faster year-over-year revenue change (112.8% vs 35.7%). Over the past eight quarters, C4 Therapeutics, Inc.'s revenue compounded faster (90.4% CAGR vs -2.7%).

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapies for cancer and other severe diseases with high unmet medical needs. It leverages its proprietary TORPEDO platform to design small molecule degraders that eliminate disease-causing proteins, with a pipeline of oncology candidates in preclinical and clinical development, plus strategic partnerships with leading global pharmaceutical firms.

Taylor Corporation is a privately owned print and communications company headquartered in North Mankato, Minnesota, and was founded in 1975 by businessman Glen Taylor. The company comprises more than 90 locations and employs nearly 10,000 employees. Taylor has print operations in dozens of U.S. states and multiple countries around the world.

CCCC vs TAYD — Head-to-Head

Bigger by revenue
TAYD
TAYD
1.1× larger
TAYD
$11.6M
$11.0M
CCCC
Growing faster (revenue YoY)
CCCC
CCCC
+77.1% gap
CCCC
112.8%
35.7%
TAYD
Higher net margin
TAYD
TAYD
203.3% more per $
TAYD
17.3%
-186.0%
CCCC
Faster 2-yr revenue CAGR
CCCC
CCCC
Annualised
CCCC
90.4%
-2.7%
TAYD

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
CCCC
CCCC
TAYD
TAYD
Revenue
$11.0M
$11.6M
Net Profit
$-20.5M
$2.0M
Gross Margin
47.0%
Operating Margin
-210.1%
19.2%
Net Margin
-186.0%
17.3%
Revenue YoY
112.8%
35.7%
Net Profit YoY
40.7%
90.2%
EPS (diluted)
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CCCC
CCCC
TAYD
TAYD
Q4 25
$11.0M
$11.6M
Q3 25
$11.2M
$9.9M
Q2 25
$6.5M
$15.6M
Q1 25
$7.2M
$10.6M
Q4 24
$5.2M
$8.5M
Q3 24
$15.4M
$11.6M
Q2 24
$12.0M
$12.1M
Q1 24
$3.0M
$12.3M
Net Profit
CCCC
CCCC
TAYD
TAYD
Q4 25
$-20.5M
$2.0M
Q3 25
$-32.2M
$2.2M
Q2 25
$-26.0M
$3.7M
Q1 25
$-26.3M
$2.0M
Q4 24
$-34.6M
$1.1M
Q3 24
$-24.7M
$2.7M
Q2 24
$-17.7M
$2.5M
Q1 24
$-28.4M
$2.7M
Gross Margin
CCCC
CCCC
TAYD
TAYD
Q4 25
47.0%
Q3 25
44.8%
Q2 25
48.6%
Q1 25
42.9%
Q4 24
45.5%
Q3 24
47.4%
Q2 24
48.8%
Q1 24
46.9%
Operating Margin
CCCC
CCCC
TAYD
TAYD
Q4 25
-210.1%
19.2%
Q3 25
-306.4%
22.6%
Q2 25
-441.0%
24.2%
Q1 25
-402.9%
19.1%
Q4 24
-728.4%
11.0%
Q3 24
-183.9%
25.0%
Q2 24
-178.6%
20.8%
Q1 24
-1060.2%
24.4%
Net Margin
CCCC
CCCC
TAYD
TAYD
Q4 25
-186.0%
17.3%
Q3 25
-286.4%
22.1%
Q2 25
-402.6%
23.7%
Q1 25
-363.7%
19.0%
Q4 24
-667.8%
12.4%
Q3 24
-160.6%
23.0%
Q2 24
-147.6%
20.5%
Q1 24
-933.2%
22.0%
EPS (diluted)
CCCC
CCCC
TAYD
TAYD
Q4 25
$-0.09
Q3 25
$-0.44
Q2 25
$-0.37
Q1 25
$-0.37
Q4 24
$-0.50
Q3 24
$-0.35
Q2 24
$-0.26
Q1 24
$-0.41

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CCCC
CCCC
TAYD
TAYD
Cash + ST InvestmentsLiquidity on hand
$74.6M
$40.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$256.6M
$67.1M
Total Assets
$359.1M
$72.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CCCC
CCCC
TAYD
TAYD
Q4 25
$74.6M
$40.7M
Q3 25
$58.8M
$36.3M
Q2 25
$78.2M
$36.0M
Q1 25
$51.3M
$35.4M
Q4 24
$55.5M
$26.6M
Q3 24
$59.6M
$27.1M
Q2 24
$73.1M
$31.0M
Q1 24
$89.7M
$24.6M
Stockholders' Equity
CCCC
CCCC
TAYD
TAYD
Q4 25
$256.6M
$67.1M
Q3 25
$154.4M
$64.3M
Q2 25
$174.1M
$62.0M
Q1 25
$195.1M
$57.8M
Q4 24
$216.0M
$55.8M
Q3 24
$242.7M
$53.9M
Q2 24
$247.1M
$51.2M
Q1 24
$258.3M
$47.8M
Total Assets
CCCC
CCCC
TAYD
TAYD
Q4 25
$359.1M
$72.8M
Q3 25
$265.5M
$70.3M
Q2 25
$296.5M
$71.6M
Q1 25
$319.5M
$70.1M
Q4 24
$349.6M
$62.9M
Q3 24
$376.1M
$61.9M
Q2 24
$381.1M
$63.1M
Q1 24
$398.4M
$54.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CCCC
CCCC
TAYD
TAYD
Operating Cash FlowLast quarter
$-22.1M
$5.7M
Free Cash FlowOCF − Capex
$4.4M
FCF MarginFCF / Revenue
38.3%
Capex IntensityCapex / Revenue
11.3%
Cash ConversionOCF / Net Profit
2.86×
TTM Free Cash FlowTrailing 4 quarters
$14.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CCCC
CCCC
TAYD
TAYD
Q4 25
$-22.1M
$5.7M
Q3 25
$-31.2M
$483.6K
Q2 25
$-12.1M
$1.9M
Q1 25
$-33.3M
$9.0M
Q4 24
$-17.9M
$103.1K
Q3 24
$-24.1M
$-3.6M
Q2 24
$-5.0M
$6.5M
Q1 24
$-18.1M
$-685.0K
Free Cash Flow
CCCC
CCCC
TAYD
TAYD
Q4 25
$4.4M
Q3 25
$-31.6M
$298.6K
Q2 25
$491.3K
Q1 25
$8.8M
Q4 24
$-17.9M
$-620.5K
Q3 24
$-24.1M
$-3.8M
Q2 24
$-5.2M
$6.1M
Q1 24
$-895.5K
FCF Margin
CCCC
CCCC
TAYD
TAYD
Q4 25
38.3%
Q3 25
-281.5%
3.0%
Q2 25
3.2%
Q1 25
83.6%
Q4 24
-346.5%
-7.3%
Q3 24
-157.2%
-33.0%
Q2 24
-43.1%
51.0%
Q1 24
-7.3%
Capex Intensity
CCCC
CCCC
TAYD
TAYD
Q4 25
11.3%
Q3 25
3.7%
1.9%
Q2 25
9.3%
Q1 25
1.8%
Q4 24
0.1%
8.5%
Q3 24
0.1%
2.1%
Q2 24
1.6%
3.3%
Q1 24
0.0%
1.7%
Cash Conversion
CCCC
CCCC
TAYD
TAYD
Q4 25
2.86×
Q3 25
0.22×
Q2 25
0.52×
Q1 25
4.51×
Q4 24
0.10×
Q3 24
-1.35×
Q2 24
2.65×
Q1 24
-0.25×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons